Abstract
Long non-coding RNAs (lncRNAs) may be a regulatory factor of tumorigenesis. However, it is unclear what its biomechanisms are in breast cancer. In this study, different lncRNAs were detected in breast cancer through microarray analysis (GSE119233) and LINC01705 was selected for further study. qRT-PCR was then utilized for the detection of LINC01705 expression in breast cancer cells. A transwell assay, flow cytometry, 5-ethynyl-2′-deoxyuridine (EdU), a cell counting Kit-8 (CCK-8), and a wound-healing assay were performed to determine cell migration, invasion, apoptosis, and proliferation in breast cancer, respectively. For the identification of potential targets of LINC01705, dual-luciferase reporter gene and bioinformatics assays were conducted. Moreover, for the clarification of their interaction and roles in the regulation of the occurrence of breast cancer, Western blotting and RIP assays were conducted. Our findings revealed high LINC01705 expression in breast cancer tissues relative to adjacent non-cancerous tissues (n = 40, P < 0.001). Overexpression of LINC01705 notably enhanced cell migration and proliferation in breast cancer. In addition, LINC01705 positively regulated the translocated promoter region, nuclear basket protein (TPR) through competition with miR-186-5p. In conclusion, our results suggest that LINC01705 is implicated in the progression of breast cancer via competitively binding to miR-186-5p as a competing endogenous RNA (ceRNA), thereby regulating TPR expression.
Highlights
Breast cancer is the most prevalent malignant tumor in females, but is one of the major causes of death from cancer in females around the world (Sarosiek, 2017)
QRT-PCR was conducted to detect LINC01705 expression in breast cancer cells (MCF-7, CAL-51, BT-20, BT-549, and AU565) and human normal mammary epithelial cells MCF 10A; high expression of LINC01705 was observed in breast cancer cells (Figure 1C)
Of the selected breast cancer cell lines, the highest and lowest levels of LINC01705 were observed in BT-549 cells and MCF-7 cells, respectively, which were selected for subsequent experiments
Summary
Breast cancer is the most prevalent malignant tumor in females, but is one of the major causes of death from cancer in females around the world (Sarosiek, 2017). According to global cancer statistics, there were over 1.7 million newly diagnosed patients with breast cancer in 2012, taking up 25% of the incidence rate of all cancers (Woolston, 2015). In breast cancer there is a trend of metastasis to distant organs (e.g., brain, lungs, liver, and bones) and a poor prognosis is observed in patients with distant metastases. Despite advances in systemic chemotherapy, the median survival of patients with metastatic breast cancer is less than 2 years (DeSantis et al, 2011; Ganz and Goodwin, 2015). In addition to existing breast cancer treatments such as surgical treatment, radiotherapy, chemotherapy, and immunotherapy, scientists need to explore more effective means of diagnosing breast cancer early, predicting its prognosis, inhibiting its metastasis, and reducing the mortality of breast cancer patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
